Opioid‑Induced Urinary Retention: Evidence‑Based Guidelines

Incidence & Risk Factors

• Up to 25 % of postoperative patients develop opioid‑induced urinary retention, most commonly during the early days of therapy. 1
• Elderly individuals are at higher risk because of benign prostatic hyperplasia and polypharmacy. 2
• Receipt of neuraxial (spinal or epidural) opioids markedly increases the likelihood of urinary retention. 3
• The first few days after initiating opioid treatment constitute the period of greatest risk for retention. 2
• Clinical presentation may be an acute inability to void or evolve into chronic urinary dysfunction. 1

Diagnostic Approach

• Immediate exclusion of spinal cord compression is required before attributing urinary retention to opioids. 2
• A comprehensive medication review should be performed to identify other agents that can impair bladder emptying (e.g., anticholinergics, benzodiazepines, α‑agonists). 1

Acute Management

• Indwelling or intermittent catheterization is indicated for patients with acute urinary retention. 2
• When feasible, the opioid regimen should be modified—either by reducing the dose or switching to a different agent—to alleviate retention. 1

Pharmacologic Interventions

First‑line

• Tamsulosin has demonstrated benefit in preventing or treating postoperative opioid‑related urinary retention. 2
• Rotating to a synthetic opioid such as fentanyl may lower the risk of retention compared with morphine or other traditional opioids. 1

Second‑line (Peripheral Opioid Antagonists)

• Methylnaltrexone (≈0.3 mg/kg IV or 12 mg SC) effectively reverses opioid‑induced urinary retention without diminishing central analgesia. 2
• Low‑dose naloxone infusion (≈0.25 mg/kg/h) can mitigate retention while preserving analgesic effect. 1

Common Pitfalls

• Failure to recognize urinary retention as a frequent opioid side effect leads to delayed or inadequate management. 4
• Attributing retention solely to other causes (e.g., benign prostatic hyperplasia, age) without considering opioid contribution can result in missed treatment opportunities. 2
• Not considering opioid rotation to fentanyl in patients with recurrent retention may prolong dysfunction. 1

Prevention Strategies

• Implement multimodal analgesia protocols to reduce overall opioid requirements and thereby lower the incidence of urinary retention. 3

Opioid‑Induced Functional Urinary Retention: Epidemiology, Mechanisms, and Management

Definition & Clinical Significance

Mechanism

Epidemiology & Risk Factors

Diagnostic Approach (Step 1)

Acute Management (Step 2)

Pharmacologic Interventions (Step 3)

First‑Line Options

Second‑Line Options (Peripheral Opioid Antagonists)

Opioid Management Strategies to Mitigate Codeine‑Induced Urinary Retention

Dose Optimization and Opioid Rotation

• Reducing the dose of codeine or rotating to a synthetic opioid such as fentanyl—both of which have been shown to carry a lower risk of urinary retention compared with codeine and morphine—can decrease the incidence of retention in patients receiving opioid analgesia for pain control. 10

Pharmacogenomic‑Guided Opioid Selection

• Patients identified as CYP2D6 ultrarapid metabolizers should be prescribed alternatives to codeine to avoid heightened toxicity, while CYP2D6 poor metabolizers should also avoid codeine because they are unlikely to achieve adequate analgesia; selecting non‑codeine opioids in these groups helps prevent both adverse effects and ineffective pain relief. 11